Elisigen's wet AMD gene therapy has been selected for the National New Drug Development Project by the KDDF. With government support, the company plans to accelerate the R&D and clinical research of NG101 for successful global market entry.
Read Original Article (Korean)
*Note: This link will redirect you to the original source in Korean.